Related Experiment Video
Updated: Dec 13, 2025
08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
5.8K
Glucocorticoid receptor modulates dendritic cell function in ulcerative colitis
Xinxin Yang1, Jingshu Geng1, Hongxue Meng1,2
1Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
Histology and Histopathology
|July 25, 2020
Summary
Ulcerative colitis (UC) treatment faces challenges with current therapies like anti-TNF and glucocorticoids (GC). Research explores dendritic cells (DCs) and their regulation by GC receptors as potential targets for new UC therapies.
Area of Science:
- Immunology
- Gastroenterology
Background:
- Ulcerative colitis (UC), a form of inflammatory bowel disease (IBD), affects patients globally.
- While anti-TNF therapies are effective for many, a significant portion remains untreated.
- Glucocorticoids (GC) are widely used but show limited long-term remission rates and non-response in 20-40% of UC patients.
Purpose of the Study:
- To review research on glucocorticoid receptor regulation of dendritic cells (DCs) in UC.
- To identify potential therapeutic targets for UC treatment.
Main Methods:
- Review of existing research on UC, anti-TNF therapy, GC treatment, and dendritic cells.
- Analysis of the role of DCs in UC pathogenesis and their interaction with GC.
Main Results:
- Increased numbers of dendritic cells (DCs) are observed in the colonic mucosa of UC patients.
- GC can inhibit DC activation by reducing MHC II expression, crucial for granulocyte recruitment.
- Adacolumn apheresis, targeting DCs, granulocytes, and monocytes, shows potential for improving intestinal tolerance.
Conclusions:
- Understanding the regulatory effect of glucocorticoid receptors on DCs is key for developing novel UC therapies.
- Targeting DC pathways offers a promising avenue for individualized and biological treatments for UC.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
328
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
328
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
364
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
364
01:24T Cell Types and Functions
1.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.9K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
343
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
343
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
727
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
727
01:15Receptor Downregulation in MVBs
2.6K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.6K